Dactolisib - Novartis/Adicet Bio
Alternative Names: BEZ-235; Dactolisib-tosylate; NVP-BEZ-235; NVP-BEZ235-ANA; NVP-BEZ235-NX; RTB-101Latest Information Update: 29 Jul 2024
Price :
$50 *
At a glance
- Originator Novartis
- Developer Adicet Bio; Brown University Medical School; Memorial Sloan-Kettering Cancer Center; Novartis
- Class 3-ring heterocyclic compounds; Acetonitriles; Anti-infectives; Antineoplastics; Antiparkinsonians; Antivirals; Benzenesulfonates; Heart failure therapies; Imidazoles; Nitriles; Quinolines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; COVID 2019 infections; Glioblastoma; Haematological malignancies; Heart failure; Influenza virus infections; Non-small cell lung cancer; Pancreatic cancer; Parkinson's disease; Perivascular epithelioid cell tumours; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma; Respiratory tract infections; Solid tumours; Urinary tract infections
Most Recent Events
- 29 Jul 2024 Discontinued - Phase-I for Heart failure (Combination therapy) in USA (PO)
- 29 Jul 2024 Discontinued - Phase-I for Parkinson's disease (Combination therapy) in USA (PO)
- 29 Jul 2024 Discontinued - Phase-I for Urinary tract infections in USA (PO)